The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | KRYSTAL-1: adagrasib in NSCLC patients with CNS metastases
Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the Phase Ib KRYSTAL-1 trial (NCT03785249) which looked into the intracranial activity of adagrasib in patients with non-small cell lung cancer (NSCLC) with stable, untreated CNS metastases. Adagrasib demonstrated promising and durable CNS activity in patients with untreated CNS metastases, where response rates were achieved in almost half of patients. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
